Is there an efficacyeffectiveness gap?
|
|
- Britton Carroll
- 6 years ago
- Views:
Transcription
1 Is there an efficacyeffectiveness gap? The observed discrepancy between effects of a health intervention in routine clinical practice as compared with the effects demonstrated in randomised controlled clinical trials. (Adapted from Eichler et al., 2011) European network for Health Technology Assessment JA September
2 Which questions do we need to address? - What are RWD? - Non-RCT data versus experimental data or EPR data - How are RWD currently being used (by HTA organisations?) - In relation to the different types of context - Guidelines on RWD versus real use RWD in HTA reports - What are possible ways forward but also hurdles? - Access to RWD for research - Quality of RWD - Usability of RWD for decision-making on pricing and reimbursement European network for Health Technology Assessment JA
3 Definition of RWD Makady A, de Boer A, Hillege H, Klungel OH, Goettsch WG,. What Is Real-World Data (RWD)? A Review of Definitions Based on Literature and Stakeholder Interviews. Value in Health 2017; 20 (7): European network for Health Technology Assessment JA
4 Some thoughts on Additional data collection through different sources Amsterdam September 14, 2017 EUnetHTA Forum
5 Starting Point Clinical Data Package The marketing authorisation shall be refused if, [ ] a. the risk-benefit balance is not considered to be favourable; or b. its therapeutic efficacy is insufficiently substantiated by the applicant; Art. 26, 2001/83/EC There is no formal requirement to include two or more pivotal studies in the phase III program. However, in most cases a program with several studies is the most, or perhaps only feasible way to provide the variety of data needed to confirm the usefulness of a product in the intended population. In the exceptional event of a submission with only one pivotal study, this has to be particularly compelling with respect to internal and external validity, clinical relevance, statistical significance, data quality, and internal consistency CPMP/EWP/2330/99 EUnetHTA Forum 2017
6 Reasons for Uncertainty Incomplete efficacy / safety data on approval Conditional marketing authorisation (2006/507/EC) Exceptional circumstances (Art. 39 No. 7, 2004/726/EC) Surrogate endpoints Rare adverse events External validity of clinical trials Population: age, (co)morbidity, co-treatments, Usage: Dosage, indication, Differences in health care systems Treatment standards Specialist availability EUnetHTA Forum 2017
7 RWD in the life cycle of technologies Use of technology in health care Comparative or full HTA / REA HTA RWD Presenting and discussing requirements studies in ED* Rapid REA STAKEHOLDERS REGU Additional data collection Assessment for market authorization Collecting evidence in Preparing submission early development. files for EMA and HTA RWD RWD RWD Time line of innovation European network for Health Technology Assessment JA *Early dialogue 15 September
8 Additional data sources Broad Categorisation Randomised Data Non-Randomised Data Randomised Clinical Trials Health Services Data, Registries, Case Series, Advantages Disadvantages Causal Relationship External validity (depends on design) Established methodology EUnetHTA Forum 2017 Recruitment of participants and investigators Advantages Disadvantages Susceptible to Bias Availability (legal and organisational framework provided) Validity and Completeness varying Methodology needs further development
9 Area of Tension Proof of Causality Prevention of Bias Closeness to Practice Best Choice? Depending on Research Question and Methodology! EUnetHTA Forum 2017
10 Value of Non-Randomised Data Norris S et al Selecting observational studies for comparing medical interventions. In: Agency for Healthcare Research and Quality. Methods Guide for Comparative Effectiveness Reviews [posted June 2010]. Rockville, MD. EUnetHTA Forum 2017
11 Availability of Health Care Data German Situation - Legal and Infrastructural constraints Possibilities Challenges Prescription data Electronic Health Records Connection of in-patient and out-patient data Validity and comprehensiveness of out-patient diagnosis information Data protection rights Legal constraints on data usage Registries EUnetHTA Forum 2017
12 Dr Michael Ermisch Pharmaceuticals Department National Association of Statutory Health Insurance Funds GKV-Spitzenverband Reinhardtstr. 28 D Berlin arzneimittel@gkv-spitzenverband.de EUnetHTA Forum 2017
13 Additional data collection through different sources Current progress in EUnetHTA JA3 Work Package 5B François Meyer HAS European network for Health Technology Assessment JA
14 EUnetHTA actions with regard to evidence generation Objective of EUnetHTA Work Package 5 on Evidence Generation To help to generate, all along the technology lifecycle, optimal and robust evidence for different stakeholders, bringing benefits for patient access and public health. Initial evidence generation: Early dialogues / WP 5 strand A Post-launch evidence generation (PLEG) / WP5 Strand B Objectives of WP5B improving post-launch evidence generation, special focus on the use of registries as data source: main activity: PLEG pilots (B1) supporting activity: Standards Tool for Registers in HTA (B2) European network for Health Technology Assessment JA
15 Overview of Strand B (PLEG & Registries) Based on previous work of EUnetHTA JA2 and the PARENT Joint Action develop collaboration for cross-border PLEG in the form of pilots for drugs and non-drug technologies (B1) Enhance the use of high-quality registries in HTA through the PLEG pilots (B1), and through the definition of Standards Tool for Registers in HTA (B2) Develop a document on the best practices for PLEG and support permanent collaboration in the field European network for Health Technology Assessment JA
16 WP5B on PLEG and registries Coordination Global coordination by HAS (WP5 lead partner) Activity centers Pilots on drugs: AIFA (Italy), TLV (Sweden) Pilots on devices: Avalia-t (Spain) Quality standards for registries: NICE (UK) European network for Health Technology Assessment JA
17 Main activity : Pilots on PLEG What are the possible levels of cross-border cooperation for PLEG: definition of the research question advice on methodology for data collection once data are produced, re-assessment of the technology (link to EUnetHTA WP4) Out of scope of EUnetHTA: Organisation and financing of data collection Cooperation is key Preparatory work necessary to identify possibilities and conditions for best cooperation European network for Health Technology Assessment JA
18 Work plan for Year 1 of the Joint Action Preparatory work : identification/analysis of: projects to collaborate with stakeholders to involve in pilots legal and practical barriers to perform pilots Done To be communicated in October 2017 PLEG pilots: In parallel, start pilot(s) on technologies in cooperation with EMA for drugs and/or H2020 projects for medical devices No technology identified at EMA or H2020 Possibility of a disease specific pilot emerged European network for Health Technology Assessment JA
19 First pilot for PLEG : Qualification of registries Qualification of registries for a rare disease, cooperation with EMA I itatio to pa ti ipate y EMA s e so t of S ie tifi Ad i e to ualify disease registries Procedure = EMA Qualification of novel methodologies for drug development: First time this exercise is performed for registries at EMA Applicant: An academic society Topics that are discussed are both quality aspects and the parameters to be recorded in registries (so that they are adapted for regulatory assessment and HTA for this condition) Outcome: qualification opinion or qualification advice PLEG pilot: 4 participants (AQuAS, HAS, INFARMED, ZIN) 4 observers (AIFA, NICE, GBA, AEMPS-HTA) European network for Health Technology Assessment JA
20 Preview of next year (WP5B1 PLEG pilots) Completion of first PLEG (disease specific) pilot (October 2017) Launch next pilots: - continue topic selection discussions by WP5B1 activity centers (deadline for second pilot topic selection: December 2017) - explore the possibility to perform disease specific pilots with other projects (e.g. IMI RoadMap, Harmony etc.) - New H2020 projects for medical devices? European network for Health Technology Assessment JA
21 Quality standards for registries WP5B Year 1 Report on current use of register data by HTA bodies Done Submitted for publication Standards for Registers in HTA First draft done and circulated to EUnetHTA partners Year 2 Production of the upgraded version of the standards tool in light of received comments First testing of the standars Pilots begin in testing agencies (AVALIA-T, AQuAS, INFARMED) using draft standards tool Completion of vision paper for independently accrediting or assuring registered using the standards tool European network for Health Technology Assessment JA
22 Conclusion Action on PLEG at EUnetHTA level Not an easy path Very necessary in the context of innovative technologies with uncertainty: innovative medical devices, orphan drugs ATMPs likely to boost the production of PLEG Cooperation to be further developed Important role of payers (Decions on CED, MEA..) European network for Health Technology Assessment JA
23 Thank you Any questions? European network for Health Technology Assessment JA
24 Registries- Regulatory Expectations Session 4: Additional data collection through different sources EUnetHTA Forum Presented by Jane Moseley on 14 September 2017 Senior Scientific Officer Scientific Advice Office An agency of the European Union
25 Disclaimer The views presented are those of the individual and may not be understood or quoted as being made on behalf of the European Medicines Agency (EMA) or reflecting the position of EMA or one of its committees or working parties Please refer to legal texts and published guidance for decision making purposes No conflicts of interest 25 Registries - Regulatory Expectations 14 September 2017
26 Regulators expectations Primary concern: benefit risk assessment through out product lifecycle For scientific question on safety/efficacy right study - high quality timely data (control of chance, bias and confounding) Important considerations 26 Definition- what is a registry What is the role of registries in evidence generation for regulators in complete data landscape Real-life Regulatory experience of registry proposals and data collection Understanding /optimising the data collected from registries Engage early with regulators for evidence generation Registries - Regulatory Expectations 14 September 2017
27 Role of registries Not about lowering regulatory standards at marketing authorisation Not to replace RCT But primarily to address important questions that we cannot answer in standard RCTs or to better understand single arm data when RCTs are not/less feasible To facilitate a strengthened life-cycle approach Recognise that today that there are important questions that we do not answer prior to first approval and cannot be addressed through RCTs 27 Registries - Regulatory Expectations 14 September 2017
28 Regulatory guidances on registries 1) PAES- Scientific guidance on post-authorisation efficacy studies Categories of uncertainties (subpopulations, co-mediation, time, endpoints, real-life use, changes in understanding/science) Registries can allow wide variety of observational study design options Data quality is crucial. Measures to ensure data quality include common terminologies, quality control and standards Limitations confounding, disease or exposure classification is not specific enough, follow-up is missing, appropriate controls cannot be identified, representativeness and generalisability, effect of time period 28 Registries - Regulatory Expectations 14 September 2017
29 Registries in regulatory guidance 2) Guideline on good pharmacovigilance practices (GVP) Module VIII Postauthorisation safety studies (Rev 2) EMA/813938/2011 Rev 2* Corr** Most suitable - rare disease, rare exposure or special population. Not normally be used to demonstrate efficacy. For: post Marketing aurhtorisaton study effectiveness in heterogeneous populations, effect modifiers, compare risks different groups 3) Guideline on safety and efficacy follow-up and risk management of Advanced Therapy Medicinal Products EMA/CHMP/65416/2016 rev.1: 4) Guideline On The Exposure To Medicinal Products During Pregnancy: Need For Postauthorisation Data EMEA/CHMP/313666/ September 2017
30 Regulatory use and experience Experiences from scientific advice (SA) 12 months advices July to June procedures, 6 advices on registries Examples proposed uses of registry data in scientific advice and regulatory responses Rare condition, for natural history, to identify prognostic markers and endpoints suitable for phase III. Regulators suggested additional clinical parameters for collection but it was questioned whether the registry could provide sufficient patients, or for long enough duration and whether a broader group of registries might be needed. Rare condition; for natural history controls for pivotal study. Regulators :- regarding historical controls, besides the suggested matches, the applicant is advised to consider a match based on country/centre to reduce bias due to different treatment methods. A confirmatory trial will still be needed. 30 Registries - Regulatory Expectations 14 September 2017
31 Regulatory use and experience Current discussions in scientific advice Rare condition; ATMP: pre-marketing Authorisation Application (MAA) discussions on nature of registry (drug vs product) for post authorisation data collection safety and effectiveness Common neurological condition: for further PreMAA discussion of use of registries/cohorts post authorisation for longer term outcomes Rare condition, imposed registry for Post Authorisation Safety Study (PASS) for preparatory advice prior to PRAC submission - Post MAA discussion Presents opportunities for parallel consultations involving other stakeholders in planning Post Launch Evidence Generation?? 31 Registries - Regulatory Expectations 14 September 2017
32 Regulatory experience at Marketing Authorisation Registries as % total MA by category 100% a legally binding requirement for a registry was included as a condition of the marketing authorisation (Annex II) 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Categories N= 32 all orphan non-orphan conditional exceptional 9% 6% 3% 1% 4% Registries - Regulatory Expectations Bouvy, J. C., Blake, K., Slattery, J., De Bruin, M. L., Arlett, P., and Kurz, X. (2017) Registries in European postmarketing surveillance: a retrospective analysis of centrally approved products, Pharmacoepidemiol Drug Saf, doi: /pds Total MA September 2017
33 Regulatory experience at Marketing Authorisation Registries % of MA category 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Categories 33 orphan non-orphan conditional exceptional 29% 4% 12% 67% Registries - Regulatory Expectations Issues: Delayed completion Delayed start Slow accrual low data quality or missing data, Disease registries preferred 14 September 2017
34 Regulatory use of registries: Conclusions 1 Existing regulatory guidance on strengths, limitations and role of registries Role in evidence generation post authorisation mainly for very rare populations post authorisation safety Endpoint development and disease epidemiology Not replacing RCT data in the main for pivotal evidence Exiting- closing the circle with the availability of post authorisation data from registries and Impact of data collection Gap in workability of registries, and scope for improvement in quality and timeliness for post authorisation evidence generation EMA registries Initiative: better use of registry data, communication, awareness raising, harmonisation tools and tasks, qualifications 34 Registries - Regulatory Expectations 14 September 2017
35 Engage early Standard Scientific Advice Why apply Conceptual/protocol agreement before implementation and investment in study protocols Focused questions associated with products, before MAA, peri MAA, early post MAA Registry holders as (part) of consortium Multiple committee engagement (paediatrics, licensing, safety, advanced therapies) Agency advice on study protocol- scientifically/morally binding Some examples as per SA 35 Registries - Regulatory Expectations 14 September 2017
36 Engage early Qualification Procedure (advice or opinion) Not product specific, consortium, 2 way or 3 way engagement with registry holders, industry, both Why apply? Definitive regulators advice /answers on specific questions, on what to improve or opinion on the suitability of the registry for regulatory purposes, committee engagement (Safety, efficacy, advanced therapies..) Supports harmonisation, quality, interoperability, usability, managing risks, across lifecycle Example disease registry X: Target population for post-approval Registry Pharmacoepidemiology/Pharmaco-economic purposes which countries, and outcomes, Which variables, data retrieval frequency, summary data vs patient level raw-data What are the barriers? Balance pragmatism vs perfectionism? 36 Registries - Regulatory Expectations 14 September 2017
37 Engage early Parallel Consultation with other stakeholders Product Specific advice Applicant questions for stakeholder e.g. will the proposed study meet the stakeholder needs in post licensing evidence generation Develop applicant s position e.g. effectiveness objective and how this is sufficient for different stakeholders needs post licensing. how a product is/will be used locally, registry only? health care expenditure/organisation of care Need to understand how registry data will be used in decision making by stakeholders in subsequent evaluations Case due to start soon; applicants encouraged to come forward 37 Registries - Regulatory Expectations 14 September 2017
38 Conclusions 2 To progress use of registry data in the regulatory context: Need for on registry based discussions on actual products and proposals for specific uses (scientific question, study design, data source) in scientific advice/parallel consultation/ qualification procedure Optimisation of data quality, timeliness, and access Identification of perceived barriers for stakeholders 38 Registries - Regulatory Expectations 14 September 2017
39 Thank you for your attention Further information Contact me at European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website Follow us
40 The Innovative Medicines Initiative: Discovery and validation of novel Role, especially in projects on big data and focus on interaction with stakeholders Nathalie Seigneuret EUnetHTA Forum, Amsterdam
41 IMI Europe s partnership for health IMI mission IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need
42 IMI Europe s partnership for health Agreement of industrial partners to work together on a real challenge for industry (non-competitive) and commit resources in kind contributions Bring new ideas from public sector, universities, SMEs etc. to address the challenge and work with industry partners competitive Calls for proposals Key to success: Scale provided through IMI funding Open collaboration in public-private consortia Outcomes should be transformative for pharma industry as well as having a clear public value to ensure that innovative medicines are developed efficiently and accessible to patients
43 IMI2 overall objectives improve the current drug development process through development of tools, standards &approaches to assess efficacy, safety & quality of health products. develop diagnostic & treatment biomarkers for diseases clearly linked to clinical relevance & approved by regulators reduce time to clinical proof of concept (e.g. for cancer, immunological, respiratory, neurological/neurodegen. diseases) increase success rate in clinical trials of priority meds (WHO) develop new therapies for diseases with high unmet need, (e.g. Alzheimer s) & limited market incentives (e.g. AMR) reduce failure rate of vaccine candidates in phase III trials through new biomarkers for efficacy & safety checks - IMI2 legislation, Article 2b
44 Examples of key areas addressed by IMI End-to-end approach from discovery through all the way to patient access of innovative medicines; Focus on unmet medical needs e.g AMR, neurodegenerative diseases Vision of personalised medicines : prevention, treatment and health management New taxonomy New targets Better understanding of disease burden Drug discovery New hits-to-lead candidates Manufacturing technologies Drug delivery Early research Early development New models Novel biomarkers Predictive models for safety Development of assays New endpoints, PROs, Clinical networks Innovative trials designs Modelling/simulation Late development Regulatory review & Patients access Benefit risk methodologies New outcome measures Digital health Patient engagement MAPPs
45 IMI Ecosystem for innovative collaborations IMI is a neutral platform where all involved in drug development can engage in open collaboration on shared challenges. All partners needed to be find transformative solutions to reduce late stage attrition, speed patient access and improve health outcomes and find solutions for a sustainable healthcare system Regulators Academia Charities SMEs Pharma companies HTA bodies Diagnostic companies Payers Healthcare practitioners Public health bodies Patients Other sectors (e.g imaging, nutrition )
46 An integrated approach closer to real life practice: real world data / big data / digital health Use of social media & novel technologies for Pharmacovigilance purposes WEB-RADR Recognising Adverse drug reactions Defining outcome based health care system Call 12 health data eco-system RADAR programme Remote Assessment of Disease and Relapse BD4BO Define and measures outcomes EHDN European Health Data Network EHR4CR Electronic health records for clinical research EMIF European Medical Information framewerk Re-use of patients level data GETREAL Incorporating Rear world data into drug development Potential of wearable devices to help prevent and treat conditions RADAR-CNS on depression, multiple sclerosis and epilepsy ADAPTSMART Medicines Adaptive Pathways to Patients Use of Electronic health records for clinical research
47 Big Data for Better Outcomes (BD4BO ) Programme Objectives: Exploit the opportunities offered by large data sets from variable sources to increase medical innovation and deliver better quality healthcare systems (= network of different health data sources) Support the evolution towards value-based and outcomes-focused sustainable healthcare delivery systems through engagement of key stakeholders
48 BD4BO programme at a glance
49 What s in the pipeline Ongoing 12th Call for proposals (deadline: 24 Oct 2017) Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer s disease (RADAR-AD) Development of sensitive and validated clinical endpoints in primary Sjögren s syndrome (PSS) European Health Data Network (EHDN) Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations For more info IMI 2018 scientific priorities under discussion IMI Think Big initiative Big data & digital health one of the areas under consideration
50 Why should HTA bodies involved in IMI? Scientific knowledge derived from many of IMI projects have direct impact on regulatory authorities, health technology assessment (HTA) bodies and payers process. Drug development more and more focused on patient experience; demonstration of real value to patients and society as a whole To ultimately ensure an end-to-end integration and maximise impact on the pharmaceutical value chain, need for engagement not only with regulators but also HTA bodies and payers. Applicant consortium asked to have in their proposal a plan for interaction with relevant milestones, resources allocated, when relevant.
51 How to get involved As full project partners by forming or joining an applicant consortium in response to an IMI Call for proposals. As members of project advisory boards to provide input to the consortium; no receipt of IMI funding (but costs may be covered by project); need to interact directly with he project. By proposing ideas for topics Benefits of engagement Influence relevance of project outputs Have access to the latest emerging science and be prepared to adapt Liaise with the network Receive funding when part of a project
52 More information Visit our website Sign up to our newsletter bit.ly/iminewsletter Follow us on Join our LinkedIn group bit.ly/linkedinimi us
53 Contact IMI
54 Disruptive Thinking Drug Development Transformation and Beyond Get ready for real life research! EORTC-EUnetHTA Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium
55
56 3 central challenges for real life data Methodological research to assess uncertainty Appropriate infrastructure and data structuring solutions A global vision to integrate new knowledge in the process leading to access in health care
57 Uncertainty in real life: Methodological gap
58 EORTC Capacities in Real-World Data Research Two cornerstones: Data The th ee pilla s of real-world data collection at EORTC Pillar 1: Merging with cancer registries Pillar 2: Registry-mediated high-resolution data collection Pillar 3: Self-reported data Research & Methodology External validity assessment ¹,² Long-term toxicity and outcome surveillance Comparative Effectiveness Research³ Randomization VS non-randomization ¹ L Liu et al Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up Br J Haematol 176 (1), ² M Thong et al A Population-Based Approach to Compare Patient-Reported Outcomes of Long-Term Hodgkin's Lymphosma Survivors According to Trial Participation: A Joint Study From the Patient-Reported Outcomes Following Initial Treatment and Long-Term Evaluation of Survivorship Registry and European Organisation for Research and Treatment of Cancer Eur J Cancer Prev Jun ³ E Kempt et al "Mind the gap" between the development of therapeutic innovations and the clinical practice in oncology: a proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimize cancer clinical research. Eur J Cancer (in press)
59 Evidence-based strategy of working with registries -a comparison of follow-up time based on 1584 patients recorded in cancer registry (IKNL) and clinical trials (EORTC)
60 50-year long-term survival, disease progression, second primary cancers, cardiovascular disease in trial participants (N=1123) VS real-world patients (N=1741) Note: Results are adjusted for baseline differences of the two populations using inverse probability weight matching method.
61 Self-reported economic status among 2026 trial patients with Hodgki s Ly pho a VS healthy controls (EUROSTAT Labor Force Survey) in 4 European countries (NL, BE, IT, Fr) General employment status Perceived impact of cancer
62 Randomization VS Non-Randomization in HTA
63 Appropriate infrastructure Data structuring
64 Real life research: the challenge of data structuring DATA PROVIDERS (DP) STEERING COMMITTEE GOUVERNANCE DATA ACCESS RULES SCIENTIFIC PEER REVIEWED DP 2 DP 3 DP DP 5 DATA REQUESTORS (R) R1 PSEUDOANONYMISED DATA IN STANDARDIZED FORMAT Access to clinical trials CENTRAL DATA REPOSITORY EORTC R2 ANONYMISED AGGREGATED DATA OUT R3 R4 R5 MANDATORY REPORTING PUBLICATION RULES --- DP 1 DATA FORMAT STANDARDIZATION VARYING ELECTRONIC MEDICAL RECORDS HOSPITALS REGISTRIES Other real life providers
65 The EORTC YOU project
66 Integration in the process to access
67 Towards a data driven healthcare From o i s to e o o i s Fo t ials desig ed to lea Early clinical trials (R&D) Biology / imaging driven Integrated TR Screening platforms Collection of high quality data from various sources to eal life situatio Pivotal trials Highly targeted Large differences Population-based studies Real world data Quality of life Health economics HTA Pragmatic trials Burock et al. Eur.J.Cancer (2013),
68 Solutions Data structuring Robust clinical evidence
69 Opportunities
70 H2020 call topic SC1-BHC : HTA research to support evidence-based healthcare Final version to be released during fall Single stage. Deadline: 10th April EU contribution: between 5 to 10 million euros. Overall project goal: To develop new or improved HTA methodological approaches and frameworks, and foster methodological consensusbuilding at the European level.
71
Strengthening the prospective discussions on post-licensing evidence generation
Strengthening the prospective discussions on post-licensing evidence generation Industry stakeholder platform on research and development support Presented by Jane Moseley on Senior Scientific Officer
More informationWhat are the real-world evidence tools and how can they support decision making?
What are the real-world evidence tools and how can they support decision making? EMA-EuropaBio Info Day 22 nd November 2016 Dr Alison Cave, Principal Scientific Administrator, Pharmacovigilance and Epidemiology
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring STAMP 4/24 Record STAMP Commission Expert
More informationThe Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels
The Innovative Medicines Initiative Europe s partnership for health Tek-Ang LIM, 20 June 2018, Brussels 10 YEARS OF LIGHTING THE WAY IMI Why Europe s partnership for health? Because despite decades of
More informationScientific advice and its impact on marketing authorisation application reviews
Scientific advice and its impact on marketing authorisation application reviews SME info day: Tools to support innovative medicines development and early access Presented by Jan Regnström, MD, PhD Scientific
More informationUse of real world data pre-authorisation what can it answer?
Use of real world data pre-authorisation what can it answer? Peter Mol -Principal assessor CBG-MEB -SAWP vice-chair (EMA) -Assistant professor, Clinical Pharmacy and Pharmacology, UMC Groningen Disclaimer
More informationEU Big Data Initiatives
European Network of Excellence for Big Data in Hematology, consisting of 51 partners from 11 countries. Aliki Taylor, HARMONY Alliance Partner Director Global Health Outcomes, Takeda EU Big Data Initiatives
More informationEMA - Early Access. PEARRL Annual Meeting 2017-Regulatory Science Symposium. University College Cork, Ireland
EMA - Early Access PEARRL Annual Meeting 2017-Regulatory Science Symposium University College Cork, Ireland Presented by Evangelos Kotzagiorgis Scientific Administrator, Quality of Medicines Office Specialised
More informationEU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective
EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development
More informationEU regulatory tools for expedited antibacterial development programmes
EU regulatory tools for expedited antibacterial development programmes Expediting antibacterial development: core lessons key tools for a rocky road, ECCMID 2018, Madrid Presented by Marco Cavaleri on
More informationThe role of patients at the EMA
The role of patients at the EMA Nathalie Bere Patient relations coordinator / European Medicines Agency An agency of the European Union What is the European Medicines Agency (EMA) The EMA is the EU regulatory
More informationConditional marketing authorisation
Conditional marketing authorisation Report on ten years of experience at the EMA Presented by Zigmars Sebris on 27 June 2017 Regulatory Affairs Office, Human Medicines Evaluation Division An agency of
More informationRegulatory point of view on clinical benefit assessment and parallel EMA/HTA advice
Regulatory point of view on clinical benefit assessment and parallel EMA/HTA advice Ateliers de Giens Meeting - French Society of Pharmacology and Therapeutics - Paris, March 23rd 2016 An agency of the
More informationEMA/CAT support to ATMP developers
EMA/CAT support to ATMP developers CAT-ISCT Workshop: Challenge and opportunities for the successful development and approval of Advanced Therapy Medicinal Products. Presented by Patrick Celis on 25 September
More informationIssues identified by stakeholders: follow-up from EMA s ATMP workshop
2 February 2017 EMA/48099/2017 Human Medicines Research and Development Support Division On 27 May 2016 EMA hosted a workshop 1 aimed to foster ATMP development and enable expanded patient access in the
More informationInnovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
More informationKPI Definition Comment Relates to Baseline Target
IMI2 Key performance indicators (KPIs) Reporting on measuring and outcomes on the ten following Key Performance Indicators will be provided yearly as part of the IMI2 JU Annual Activity Reports for year
More informationUpdate on Real World Evidence Data Collection
Update on Real World Evidence Data Collection STAMP, 10 March 2016 Presented by Dr Peter Arlett EMA An agency of the European Union What is Real-world evidence? Big data = umbrella term describing large
More informationEngagement with stakeholders
Engagement with stakeholders 2 nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency Presented by Juan Garcia Burgos and Marie-Helene Pinheiro on 8 March
More informationPRIority MEdicines (PRIME)
PRIority MEdicines (PRIME) Support to development of priority medicines for unmet medical needs. EuropaBIO information day, 15 October 2015 Jordi Llinares, Head of product development scientific support.
More informationUse of RWE in a regulatory context: issues and examples. Rob Hemmings, MHRA
Use of RWE in a regulatory context: issues and examples Rob Hemmings, MHRA Disclaimer I don t particularly like the terms real world data, real world evidence. To be more precise, I will discuss data generated
More informationEuropean contribution to the RWD/RWE debate. Alasdair Breckenridge July 2018
European contribution to the RWD/RWE debate Alasdair Breckenridge July 2018 Sources UK Academy of Medical Sciences(AMS) workshops European Medicines Agency (EMA) Innovative Medicines Initiative (IMI) projects
More informationOverview of the Agency s role, activities and priorities for An agency of the European Union
Overview of the Agency s role, activities and priorities for 2015 An agency of the European Union The Agency's prioroties for 2015 In light of the above influences and other business-environment factors,
More informationIMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
More informationRegulatory Support to EU Research
Regulatory Support to EU Research OPEN INFO DAY Horizon 2020 'Health, demographic change and wellbeing Friday, 8 December 2017 Brussels Presented by Marisa Papaluca Senior Scientific Advisor, Scientific
More informationRegulatory update from Europe:
Regulatory update from Europe: Procedures to promote early access of medicinal products to the market Elmer Schabel MD Regulatory update from Europe - Overview Current tools for early access Conditional
More informationInnovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
More informationMarketing Authorisation Routes in the EU
Marketing Authorisation Routes in the EU The EU medicines regulatory system and the European Medicines Agency: an introduction for international regulators and non-governmental organisations 18 September
More informationWebinar IMI2 Call 13 CONCEPTION continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
Webinar IMI2 Call 13 CONCEPTION continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now 11 December 2017 15:00 CET Agenda How to use GoToWebinar
More informationThe EU Risk Management Plan - a tool to address the uncertainties at the time of approval, and manage the risks of medicines
The EU Risk Management Plan - a tool to address the uncertainties at the time of approval, and manage the risks of medicines Health care uncertainty assessment workshop Session 3: The challenges of health
More informationHTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned?
HTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned? DIA 26th Annual EuroMeeting, Vienna 2014 Jan Regnstrom, MD, PhD Senior Scientific Officer An agency
More information1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States
PRESS 17/6/2016 PRESS RELEASE Council of the European Union 1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States "The Council of the European
More informationRWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
More informationMoving HTA forward: The challenges of incorporating real world evidence into Health Technology Assessment
Moving HTA forward: The challenges of incorporating real world evidence into Health Technology Assessment Matthias Egger Mike Chambers Univ. of Berne, Switzerland GSK, UK Slide 1 Increasingly complex external
More informationFinal report on the adaptive pathways pilot
28 July 2016 EMA/276376/2016 European Medicines Agency Summary In March 2014 EMA launched a pilot project to explore the adaptive pathways approach, a scientific concept of medicines development and data
More informationEMA Adaptive licensing: a tool concept for accelerated access to innovative medicines? Rob Hemmings, MHRA
EMA Adaptive licensing: a tool concept for accelerated access to innovative medicines? Rob Hemmings, MHRA Slides largely re-produced from a previous EMA presentations to (DIA, Paris; STAMP, Brussels).
More informationFive years as EMA Liaison at US FDA
Five years as EMA Liaison at US FDA TOPRA Annual Human Medicines Symposium 2 4 October 2017 - Victoria Park Plaza Hotel, London Presented by Dr Sabine Haubenreisser on 2 October 2017 European Medicines
More informationWebinar IMI2 Call 13 Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
Webinar IMI2 Call 13 Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative 27.11.2017 15:00 CET Agenda How to use GoToWebinar Catherine Brett,
More informationPRIME. 7 th STAMP meeting Brussels, 27 th June Presented by Sonia Ribeiro Head of Regulatory Affairs Office, Human Medicines Evaluation Division
PRIME 7 th STAMP meeting Brussels, 27 th June 2017 Presented by Sonia Ribeiro Head of Regulatory Affairs Office, Human Medicines Evaluation Division An agency of the European Union Overview of one-year
More informationCoordination and Support Action: Enabling platform on medicines adaptive pathways to patients
Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients Solange Rohou (AZ) & Luk Maes (BMS) 17.12.2014 IMI webinar Content Background information CSA project proposal
More informationAdvanced Therapies in Europe
Advanced Therapies in Europe 1 ATMPs in Europe (2009-2017) ~ 500 clinical trials using ATMPs in EU ~ 270 ATMP classifications 18 MAAs reviewed ~ 250 scientific advice requests 9 ATMPs approved 2 3 withdrawn
More informationThe Innovative Medicines Initiative Socio-economic impacts
The Innovative Medicines Initiative Socio-economic impacts Pierre Meulien, IMI Executive Director European Innovation Summit European Parliament 08.12.2015 Closed & open innovation Filing Approval HTA
More informationInnovative Medicines Initiative:
Innovative Medicines Initiative: Opportunities for local players to become important parts of multicountry pharma innovation Nathalie Serigneuret 4 March 2015 Clinical Trials Conference 2015, Budapest
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. STAMP Commission Expert Group 10 March 2016
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring STAMP 4/23 rev.1 STAMP Commission Expert
More information6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels
www.eurordis.org 6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels Brussels, 24-25 May 2012 www.eurordis.org THE NEW PARADIGMS OF RARE DISEASES TREATMENT DEVELOPMENT & ACCESS
More informationRecent update of the guidance for Parallel EMA/FDA scientific advice
Recent update of the guidance for Parallel EMA/FDA scientific advice Industry stakeholder platform on research and development support, 15.11.2017 Presented by Thorsten Vetter An agency of the European
More informationABPI response to European Commission consultation on advanced therapy medicinal products
ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal
More informationWork programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board
18 December 2014 EMA/773839/2014 Rev. 1 Management Board Work programme 2015 Adopted by the Management Board on 18 December 2014 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationClinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA
Clinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA TELETHON Convention, Riva del Garda (TN) 15 March 2017 Michela Gabaldo Head Alliance Management & Regulatory
More informationSurvey report European Medicines Agency (EMA) consultation on the proposal of a collaboration framework with academia
20 October 2016 Stakeholders and Communication Division Survey report European Medicines Agency (EMA) consultation on the proposal of a collaboration framework with academia 30 Churchill Place Canary Wharf
More informationPriority Medicines (PRIME) scheme
Priority Medicines (PRIME) scheme DGRA Congress, Bonn, 15 June 2016 Presented by Christelle Bouygues Regulatory Affairs Officer An agency of the European Union Outline Why Prime? What is PRIME? PRIME Eligibility
More informationUsing local RWD to drive global therapeutic advancements.
Using local RWD to drive global therapeutic advancements. Helsinki, 30 th Nov 2016 Mike Spencer, Head of Real World Evidence, EMEA, Janssen The following represent my own views and not necessarily those
More informationEUnetHTA. European network for Health Technology Assessment. European network for Health Technology Assessment JA
EUnetHTA European network for Health Technology Assessment Outline The Making of EUnetHTA EUnetHTA and the HTA Network EUnetHTA Achievements and Tools General Information about HTA 2 The Making of EUnetHTA
More informationPersonalised Medicine Regulatory Issues
Personalised Medicine Regulatory Issues INFRAFRONTIER / IMPC Stakeholder Meeting Presented by Marisa Papaluca on 14 November 2017 Senior Scientific Advisor, Scientific Committees Regulatory Science Strategy
More informationOptimising early access tools: Revision of the guidelines on Accelerated Assessment and Conditional Marketing Authorisation
Optimising early access tools: Revision of the guidelines on Accelerated Assessment and Conditional Marketing Authorisation High-level overview of comments received during the public consultation Presented
More informationAccelerated Approvals
Accelerated Approvals An Industry Perspective Kumeshnie Padayachee University of Pretoria 09 September 2015 Table of Contents ZA Expedite Review Process Fast Track Overview of FDA Expedited Pathways: Focus
More informationThe Role of Public-Private Partnerships & Evidence Generation
The Role of Public-Private Partnerships & Evidence Generation Christina Donatti LLB, BSc, MSc, PsyD IMI Lead, RWE EMEA Strategic Organisation. Janssen Cilag Janssen is proud to feature artwork created
More informationUse of Real World Data in Development Programmes
Use of Real World Data in Development Programmes Dr Alison Cave and Dr Francesca Cerreta Industry Stakeholder Platform on Research and Development Support 25 April 2017 An agency of the European Union
More informationSPECTArare as an innovative model of combining clinical research and care in an ERN. Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium
SPECTArare as an innovative model of combining clinical research and care in an ERN Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium Contents The changing clinical research pathway How
More informationConsiderations on regulatory aspects
Considerations on regulatory aspects Regulatory framework for medicinal products in the context of therapeutic use of bacteriophages EMA Workshop on 8 June Presented by Zigmars Sebris on 8 June 2015 Regulatory
More informationThe Innovative Medicines Initiative. Pierre Meulien CNIO, Madrid - Spain
The Innovative Medicines Initiative Pierre Meulien 12.01.2017 CNIO, Madrid - Spain IMI Europe s partnership for health > 5 bn 2.5 bn Partnership 2008-2020 Pharma industry 2.5 bn EU contribution from FP7
More informationPersonalised medicine towards the market and patients: the approval process
An agency of the European Union Personalised medicine towards the market and patients: the approval process European Medicines Agency s perspective Presented by: Marisa Papaluca Amati Human Medicines Development
More informationTopic: Genome-Environment Interactions in Inflammatory Skin Disease
Topic: Genome-Environment Interactions in Inflammatory Skin Disease All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be
More informationEUCERD RECOMMENDATION FOR A
EUCERD RECOMMENDATION FOR A CAVOMP INFORMATION FLOW RECOMMENDATION OF THE EUROPEAN UNION COMMITTEE OF EXPERTS ON RARE DISEASES TO THE EUROPEAN COMMISSION AND THE MEMBER STATES ON IMPROVING INFORMED DECISIONS
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationPROPOSAL and DISCUSSION
PROPOSAL and DISCUSSION Towards a European One-Stop Provider of aggregated RWE data in Multiple Sclerosis for regulators, payers, academia and patient advocates? Prepared by: Christoph Thalheim, EMSP For
More informationEarlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot
Earlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot World Stem Cells & Regenerative Medicine 2014 Dr Daniel O Connor Disclaimer The views expressed do not necessarily
More informationNew pharmacovigilance systems and services
New pharmacovigilance systems and services 17 September 2015, PCWP/HCPWP joint meeting Presented by Peter Arlett, Head of Pharmacovigilance department An agency of the European Union Background The new
More informationSubmission of comments on COMMISSION NOTICE ON THE APPLICATION OF ARTICLES 3, 5 AND 7 OF REGULATION (EC) NO 141/2000 ON ORPHAN MEDICINAL PRODUCTS
Ref. Ares(2016)807620-16/02/2016 15 February 2016 Submission of comments on COMMISSION NOTICE ON THE APPLICATION OF ARTICLES 3, 5 AND 7 OF REGULATION (EC) NO 141/2000 ON ORPHAN MEDICINAL PRODUCTS Response
More informationATMPs guideline on Safety and Efficacy follow-up and risk management
ATMPs guideline on Safety and Efficacy follow-up and risk management Presented by Caroline Voltz-Girolt EMA Product Lead - Oncology, Haematology and Diagnostics Office Scientific and Regulatory Management
More informationComments from: Name of organisation or individual. Merck Sharp & Dohme (MSD)
5 November 2015 EMA/733775/2015 Product Development Scientific Support Department Overview of comments on Total Kidney Volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients
More informationNeurodegeneration and other neuroscience priorities
Potential future IMI Call topics About this document The following topics are under consideration for inclusion in future IMI Calls for proposals in the longer term. The discussions on these topics are
More informationCoordination and Support Action (CSA) for the Big Data for Better Outcomes programme. Stephan Korte, Kim Cryns
Coordination and Support Action (CSA) for the Big Data for Better Outcomes programme Stephan Korte, Kim Cryns 11.01.2016 IMI webinar Big Data for Better Outcomes (BD4BO) Initiative within IMI2 Goal Support
More informationStakeholder Consultation Strategy
Stakeholder Consultation Strategy Strengthening of the EU cooperation on Health Technology Assessment (HTA) 1. Context The present stakeholder consultation aims to provide broad and high quality information
More informationWebinar IMI2 - Call 15 Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease
Webinar IMI2 - Call 15 Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease 09.07.2018 Agenda How to use GoToWebinar Catherine Brett, IMI Introduction Iwona Jablonska,
More informationPosition Paper. Executive Summary
Position Paper Status: Final Date of document: 10.10.2017 Hospital Exemption for Advanced Therapy Medicinal Products (ATMPs): greater transparency needed in order to improve patient safety and access to
More informationExplanatory note on fees payable to the European Medicines Agency
30 March 2015 EMA/167155/2014 Executive Director Explanatory note on s payable to the European Medicines Agency The s, exemptions and definitions described in this Explanatory Note apply as of 1 April
More informationBD4BO and ROADMAP: a collaborative approach to set new standards for the collation and evaluation of RWE in Alzheimer s Disease
BD4BO and ROADMAP: a collaborative approach to set new standards for the collation and evaluation of RWE in Alzheimer s Disease Impact of Big Data Analytics on Healthcare 4-5 October 2017, Luxembourg Dr
More informationFrom IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014
From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the
More informationCertification in Pharmaceutical Medicine and Clinical Research The vision of regulators
Certification in Pharmaceutical Medicine and Clinical Research The vision of regulators Presented by Sergio Bonini Professor of Medicine, Second University of Naples Expert-on-Secondment, European Medicine
More informationWebinar IMI2 Call 14 Opportunities for SMEs
Webinar IMI2 Call 14 Opportunities for SMEs 19 March 2018 Agenda How to use GoToWebinar Catherine Brett, IMI Opportunities for SMEs Colm Carroll, IMI Questions & answers How to use GoToWebinar - audio
More informationFirst Plenary Session CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE. Jean-Luc Harousseau, MD
First Plenary Session Speaker CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE Jean-Luc Harousseau, MD President and Chairman of the Board Haute Autorité de Santé (HAS) Saint-Denis La Plaine, France HTA
More informationFollowing Cancer Drug Pathways from Inception to Launch: Partnership, prospects and Pitfalls. Katie Pascoe (Value and Access, ABPI) 22 September 2016
Following Cancer Drug Pathways from Inception to Launch: Partnership, prospects and Pitfalls Katie Pascoe (Value and Access, ABPI) 22 September 2016 Partnering is a key factor in patient access to new
More informationThe Integration of Market Access and Advocacy: The Changing Landscape OCTOBER 2016
The Integration of Market Access and Advocacy: The Changing Landscape OCTOBER 2016 The Integration of Market Access and Advocacy: The Changing Landscape Introduction Healthcare market access and advocacy
More informationIntroduction to IMI. Pierre Meulien Executive Director Innovative Medicines Initiative
Introduction to IMI Pierre Meulien Executive Director Innovative Medicines Initiative What is the Innovative Medicines Initiative? EU funding goes to: - universities - SMEs - patient groups etc 2.5 bn
More informationAuthorisation of ATMPs in EU: routes to facilitate prompt availability for patients.
Authorisation of ATMPs in EU: routes to facilitate prompt availability for patients. This presentation only reflects the views of its author and does not necessarily reflect the opinion of the Commission
More informationThe European Health Data & Evidence Network
The European Health Data & Evidence Network What is it? Nigel Hughes EFPIA Coordinator Scientific Director, JCI Patient Data for Research, Janssen 18 th May 2018 1 All too often real world research is
More informationVALUE ADDED MEDICINES. Prof. Mondher Toumi, Professor of Public Health, Aix-Marseille University
VALUE ADDED MEDICINES Prof. Mondher Toumi, Professor of Public Health, Aix-Marseille University What Are Value Added Medicines? Value added medicines are defined as medicines based on known molecules that
More informationPublications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity
Publications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity OBJECTIVES FOR THE SESSION To be able to build payer evidence requirements into publication
More informationAdaptive pathways workshop briefing book
Adaptive pathways workshop briefing book Readers guidance Follow us on Twitter #AdaptivePathways About this briefing book This document is preparatory reading material for the adaptive pathways workshop.
More informationSzabolcs Barotfi Ph.D.
Szabolcs Barotfi Ph.D. Manufacturer: Bayer Withdrawn in 2001 (4 years after registration) Financial loss: 1.2 bn $ Manufacturer: MSD Withdrawn in 2004 (5 years after registration) Financial loss: 2 bn
More informationPharmacovigilance: Information systems and services
Pharmacovigilance: Information systems and services Supporting business activities of the revised pharmacovigilance legislation through better information systems An agency of the European Union To deliver
More informationStakeholders engagement
Stakeholders engagement The EU medicines regulatory system and the European Medicines Agency: an introduction for international regulators and non-governmental organisations 18-19 September 2017 Presented
More informationFinal - Minutes of EMA/EUnetHTA meeting
10 May 2017 EMA/826577/2016 7 December 2016 Co-chairs: Hans-Georg Eichler (EMA) and Wim Goettsch (EUnetHTA) Role Chairs: Present: Name Hans-Georg Eichler and Wim Goettsch EUnetHTA: Wim Goettsch, Michelle
More informationWork programme July 2016 EMA/92499/2016 Rev. 1 1 Executive Director. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
5 July 2016 EMA/92499/2016 Rev. 1 1 Executive Director 1 Procurement plan added (annex 5) 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20
More informationAccelerated Development of Appropriate Patient Therapies
Accelerated Development of Appropriate Patient Therapies A Sustainable, Multi-stakeholder Approach for MAPPS - Medicines Adaptive Pathways to Patients André Broekmans Coordinator Adapt Smart Work Package
More informationOverview of recent changes in the centralised procedure
Overview of recent changes in the centralised procedure 2 nd Industry stakeholder platform, 9 November 2015 Presented by: Michael Berntgen Head of Scientific & Regulatory Management Department An agency
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring STAMP 6/31 Summary record STAMP Commission
More informationRWE: FROM NICE TO HAVE TO MUST HAVE
White Paper RWE: FROM NICE TO HAVE TO MUST HAVE Are you ready to meet healthcare stakeholders ever-increasing evidence demands? MARKUS GORES, Vice President, Real-world & Analytics Solutions, IQVIA DONY
More informationSummary of Product Characteristics Advisory Group (SmPC AG) activity report
14 March 2016 Scientific and Regulatory Management Department Summary of Product Characteristics Advisory Group (SmPC AG) 2010-2015 activity report Quality assurance of SmPCs 1. Introduction During the
More information